Company intelligence / Profile preview

GIOSTAR

San Diego, California, United Statesgiostar.com ↗

Ownership: Private
Development stage: Phase 1

Overview

FDA cleared IND application to start Phase 2 clinical trial for DT2-SCT (stem cell therapy for Type II diabetes) in 2024. Previously received FDA compassionate use clearance for stem cells for COVID-19.

Therapeutic areas: Metabolic DisordersOncologyEndocrinologyImmunologyHematologyRheumatologyNeurologyInfectious Diseases
Modalities: Stem cell therapiesCellular therapiesMesenchymal stem cellsNeural Precursor CellsInduced Pluripotent Stem Cells (iPSCs)
Industry: Biotech

Drug pipeline

1 asset

DT2-SCT

Partnerships

TAG Investment Bankers LTD of London

Beyond the preview

Go deeper on GIOSTAR.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GIOSTAR.

Explore the full profile